Endogenous CSF CGRP (upregulated on days 1 to 4 after sSAH) [33] and exogenously administered CGRP are postulated to be cerebroprotective and, thus, beneficial for functional outcome by preventing sSAH-induced CV and cerebral ischemia, respectively [28, 29]. This evidence concerns the gene CALCA and brain ischemia.